Tonix Pharmaceuticals Holding (TNXP) Accumulated Expenses (2010 - 2026)

Tonix Pharmaceuticals Holding has reported Accumulated Expenses for 17 years, with the latest figure at $21.5 million in Q2 2026.

• On a quarterly basis, Accumulated Expenses rose 93.85% year-over-year to $21.5 million in Q2 2026; TTM through Jun 2026 was $21.5 million, a 93.85% increase from a year earlier, with the FY2025 full-year figure at $22.6 million, up 111.85% from the prior year.
• Accumulated Expenses was $21.5 million for Q2 2026 at Tonix Pharmaceuticals Holding, up from $19.8 million in the prior quarter.
• The five-year high for Accumulated Expenses was $22.6 million in Q4 2025, with the low at $4.6 million in Q1 2023.
• Average Accumulated Expenses over 5 years is $11.1 million, with a median of $10.0 million recorded in 2022.
• The sharpest annual moves came in 2025 and 2026: Accumulated Expenses slipped 28.09% in 2025, then jumped 157.01% in 2026.
• Over 5 years, Accumulated Expenses stood at $9.7 million in 2022, then gained by 28.95% to $12.5 million in 2023, then slipped by 14.54% to $10.7 million in 2024, then surged by 111.85% to $22.6 million in 2025, then retreated by 4.93% to $21.5 million in 2026.
• The last three Accumulated Expenses figures came in at $21.5 million (Q2 2026), $19.8 million (Q1 2026), and $22.6 million (Q4 2025), per Business Quant data.